Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer
James E. Korkola(Oregon Health & Science University), Joe W. Gray(University of Newcastle Australia), Gordon B. Mills(The University of Texas MD Anderson Cancer Center), Yiling Lu(The University of Texas MD Anderson Cancer Center), Heidi S. Feiler(Oregon Health & Science University), Eric A. Collisson(City College of San Francisco), Wallace Thompson(Oregon Health & Science University), Paul T. Spellman(Oregon Health & Science University), Claire J. Tomlin(Vaughn College of Aeronautics and Technology), Lakshmi R. Jakkula(Lawrence Berkeley National Laboratory), Jessica I. Billig(Southwestern Medical Center), Chris J. Oates(The Netherlands Cancer Institute), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Laura M. Heiser(Oregon Health & Science University), Amanda Esch(Oregon Health & Science University), Brian A. Cooper(Lawrence Berkeley National Laboratory), Wen Lin Kuo(Lawrence Berkeley National Laboratory), Sleiman Itani(University of California, Berkeley), Sach Mukherjee(German Center for Neurodegenerative Diseases), Nora Bayani(Lawrence Berkeley National Laboratory), Obi L. Griffith(Washington University in St. Louis), Nicholas J. Wang(Oregon Health & Science University), Jenny L. Hung(Lawrence Berkeley National Laboratory)
Cited by 28
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
The chromatin accessibility landscape of primary human cancers
|Science|2018|1.3k